Europe Contract Research Organization (CRO) Market Research Report Forecast to 2030
The growth of the Europe contract research organization (CRO) market is attributed to the increasing R&D expenditure in Europe, the rising number of clinical trials, digital transformation in clinical trials, and growing CRO outsourcing in drug development. However, a shortage of skilled and experienced professionals and stringent regulatory policies are anticipated to hamper the market growth.
A contract research organization also called a Clinical Research Organization (CRO), provides support to the pharmaceutical and biotechnology industries in the form of outsourced pharmaceutical research services (for both drugs and medical devices). CROs also offer the experience of advancing a new drug or device from its inception to FDA marketing approval to their clients without the drug sponsor needing to maintain a staff for these services. CROs range from huge, international full-service businesses to small, niche specialty groups.
The Europe Contract Research Organization (CRO) market is emerging due to factors the increasing R&D expenditure in Europe, the rising number of clinical trials, and the growing CRO outsourcing in drug development. Additionally, the digital transformation in clinical trials will provide growth opportunities for the market in the future. However, the shortage of skilled and experienced professionals and stringent regulatory policies might hamper the market's growth in the forecast period.
Market SegmentationIn terms of Type, Europe Contract research organization is classified into Phase I, phase II, phase III, and Phase IV clinical trial services.
Based on applications the market is classified into Oncology, Cardiovascular, Autoimmune/Inflammation, Central Nervous System (CNS), Dermatology, Infectious Diseases, and Others.
The end-user industry is made up of Pharmaceutical and Biopharmaceutical Companies, Research Laboratories, and Others.
Regional AnalysisThe increasing investment in R&D programs, patent expiration in the healthcare sector, and preference for outsourcing activities due to time & cost constraints are key factors anticipated to drive the Europe Contract Research Organization (CRO) market. In addition, increasing government support to research institutes and companies for R&D activities through grants and funds has further boosted the regional market. For instance, in 2021, the European government invested USD 109 billion in medical and health R&D. This is attributed to the high prevalence of chronic conditions, a fast-growing pharmaceutical market, a treatment-naive patient pool, access to a large, favorable, and harmonized regulatory environment, and strong Intellectual Property (IP) and legal Infrastructure. In addition, the availability of skilled professionals having experience with regulations and numerous large-scale, advanced clinical trial centers and specialized disease centers with therapeutic area expertise is further boosting regional growth.
Major PlayersCharles River Laboratories, IQVIA, Laboratory Corporation of America Holdings, Thermo Fisher Scientific Inc., and ICON plc.
Companies MentionedCharles River Laboratories
IQVIA
Laboratory Corporation of America Holdings
Thermo Fisher Scientific Inc.
and ICON plc.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.